References
Key articles
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report. 2026 [internet publication].Full text
National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Jul 2019 [internet publication].Full text
Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 May 1;201(9):e56-69.Full text Abstract
Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-41. [Erratum in: Am J Respir Crit Care Med. 2021 Apr 15;203(8):1045-6.]Full text Abstract
Reference articles
1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report. 2026 [internet publication].Full text
2. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Jul 2019 [internet publication].Full text
3. Garcia-Pachon E. Paradoxical movement of the lateral rib margin (Hoover sign) for detecting obstructive airway disease. Chest. 2002 Aug;122(2):651-5. Abstract
4. Maignan M, Chauny JM, Daoust R, et al. Pain during exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. PLoS One. 2019 May 24;14(5):e0217370.Full text Abstract
5. Morgan AD, Rothnie KJ, Bhaskaran K, et al. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. Thorax. 2018 Sep;73(9):877-9. Abstract
6. Maltais F, Decramer M, Casaburi R, et al; ATS/ERS Ad Hoc Committee on Limb Muscle Dysfunction in COPD. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014 May 1;189(9):e15-62.Full text Abstract
7. Nissen F, Morales DR, Mullerova H, et al. Concomitant diagnosis of asthma and COPD: a quantitative study in UK primary care. Br J Gen Pract. 2018 Nov;68(676):e775-82.Full text Abstract
8. Hosseini M, Almasi-Hashiani A, Sepidarkish M, et al. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019 Oct 23;20(1):229.Full text Abstract
9. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countries. Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1131-41.Full text Abstract
10. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021 Mar 6;397(10277):928-40. Abstract
11. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022 May;10(5):447-58.Full text Abstract
12. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ. 2022 Jul 27;378:e069679.Full text Abstract
13. Li X, Cao X, Guo M, et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020 Feb 19;368:m234. [Erratum in: BMJ. 2020 Aug 6;370:m3150.]Full text Abstract
14. Liu Y, Carlson SA, Watson KB, et al. Trends in the prevalence of chronic obstructive pulmonary disease among adults aged ≥18 years - United States, 2011-2021. MMWR Morb Mortal Wkly Rep. 2023 Nov 17;72(46):1250-6.Full text Abstract
15. Tilert T, Dillon C, Paulose-Ram R, et al. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010. Respir Res. 2013 Oct 9;14(1):103.Full text Abstract
16. Ma J, Ward EM, Siegel RL, et al. Temporal trends in mortality in the United States, 1969-2013. JAMA. 2015 Oct 27;314(16):1731-9.Full text Abstract
17. QuickStats: percentage of adults aged ≥18 years with diagnosed chronic obstructive pulmonary disease, by urbanization level and age group - National Health Interview Survey, United States, 2019. MMWR Morb Mortal Wkly Rep. 2021 Jul 2;70(26):959.Full text Abstract
18. Varmaghani M, Dehghani M, Heidari E, et al. Global prevalence of chronic obstructive pulmonary disease: systematic review and meta-analysis. East Mediterr Health J. 2019 Mar 19;25(1):47-57.Full text Abstract
19. Landis SH, Muellerova H, Mannino DM, et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis. 2014 Jun 6;9(1):597-611.Full text Abstract
20. Han MK. Chronic obstructive pulmonary disease in women: a biologically focused review with a systematic search strategy. Int J Chron Obstruct Pulmon Dis. 2020 Apr 1;15:711-21. [Erratum in: Int J Chron Obstruct Pulmon Dis. 2021 Nov 4;16:3017-8.]Full text Abstract
21. Lamprecht B, McBurnie MA, Vollmer WM, et al; BOLD Collaborative Research Group. COPD in never smokers: results from the population-based Burden of Obstructive Lung Disease study. Chest. 2011 Apr;139(4):752-63.Full text Abstract
22. Syamlal G, Doney B, Mazurek JM. Chronic obstructive pulmonary disease prevalence among adults who have never smoked, by industry and occupation - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2019 Apr 5;68(13):303-7.Full text Abstract
23. Syamlal G, Kurth LM, Dodd KE, et al. Chronic obstructive pulmonary disease mortality by industry and occupation: United States, 2020. MMWR Morb Mortal Wkly Rep. 2022 Dec 9;71(49):1550-4.Full text Abstract
24. World Health Organization. Smoking is the leading cause of chronic obstructive pulmonary disease. Nov 2023 [internet publication].Full text
25. Lugg ST, Scott A, Parekh D, et al. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. Thorax. 2022 Jan;77(1):94-101.Full text Abstract
26. Park J, Kim HJ, Lee CH, et al. Impact of long-term exposure to ambient air pollution on the incidence of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Environ Res. 2021 Mar;194:110703.Full text Abstract
27. Zhu RX, Nie XH, Chen YH, et al. Relationship between particulate matter (PM2.5) and hospitalizations and mortality of chronic obstructive pulmonary disease patients: a meta-analysis. Am J Med Sci. 2020 Jun;359(6):354-64. Abstract
28. Peng C, Yan Y, Li Z, et al. Chronic obstructive pulmonary disease caused by inhalation of dust: a meta-analysis. Medicine (Baltimore). 2020 Aug 21;99(34):e21908.Full text Abstract
29. Faruque MO, Boezen HM, Kromhout H, et al. Airborne occupational exposures and the risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study. Thorax. 2021 Mar 2;76(8):790-7.Full text Abstract
30. Lytras T, Kogevinas M, Kromhout H, et al. Occupational exposures and 20-year incidence of COPD: the European Community Respiratory Health Survey. Thorax. 2018 Nov;73(11):1008-15.Full text Abstract
31. Shin S, Bai L, Burnett RT, et al. Air pollution as a risk factor for incident chronic obstructive pulmonary disease and asthma. A 15-year population-based cohort study. Am J Respir Crit Care Med. 2021 May 1;203(9):1138-48. Abstract
32. Liu S, Lim YH, Pedersen M, et al. Long-term air pollution and road traffic noise exposure and COPD: the Danish Nurse Cohort. Eur Respir J. 2021 Dec 2;58(6):2004594. Abstract
33. Eapen MS, Sohal SS. Update on the pathogenesis of COPD. N Engl J Med. 2019 Dec 19;381(25):2483-4. Abstract
34. Lange P, Celli B, Agustí A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015 Jul 9;373(2):111-22.Full text Abstract
35. Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. Thorax. 2005 Oct;60(10):851-8.Full text Abstract
36. Balte P, Karmaus W, Roberts G, et al. Relationship between birth weight, maternal smoking during pregnancy and childhood and adolescent lung function: a path analysis. Respir Med. 2016 Dec;121:13-20.Full text Abstract
37. David B, Bafadhel M, Koenderman L, et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021 Feb;76(2):188-95.Full text Abstract
38. Gharib SA, Manicone AM, Parks WC. Matrix metalloproteinases in emphysema. Matrix Biol. 2018 Nov;73:34-51.Full text Abstract
39. Mecham RP. Elastin in lung development and disease pathogenesis. Matrix Biol. 2018 Nov;73:6-20.Full text Abstract
40. Kovacs G, Avian A, Bachmaier G, et al. Severe pulmonary hypertension in COPD: impact on survival and diagnostic approach. Chest. 2022 Jul;162(1):202-12.Full text Abstract
41. Chen P, Li Y, Wu D, et al. Secondhand smoke exposure and the risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:1067-76.Full text Abstract
42. Wold LE, Tarran R, Crotty Alexander LE, et al. Cardiopulmonary consequences of vaping in adolescents: a scientific statement from the American Heart Association. Circ Res. 2022 Jul 22;131(3):e70-82.Full text Abstract
43. Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: a scientific statement from the American Heart Association. Circulation. 2023 Aug 22;148(8):703-28.Full text Abstract
44. World Health Organization. WHO tobacco knowledge summaries: tobacco and chronic obstructive pulmonary disease (COPD). Nov 2023 [internet publication].Full text
45. Blanco I, Diego I, Bueno P, et al. Prevalence of alpha1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev. 2020 Jul 21;29(157):200014.Full text Abstract
46. Li LS, Paquet C, Johnston K, et al. "What are my chances of developing COPD if one of my parents has the disease?" A systematic review and meta-analysis of prevalence of co-occurrence of COPD diagnosis in parents and offspring. Int J Chron Obstruct Pulmon Dis. 2017 Jan 24;12:403-15.Full text Abstract
47. Bellou V, Belbasis L, Konstantinidis AK, et al. Elucidating the risk factors for chronic obstructive pulmonary disease: an umbrella review of meta-analyses. Int J Tuberc Lung Dis. 2019 Jan 1;23(1):58-66. Abstract
48. Gilkes A, Hull S, Durbaba S, et al. Ethnic differences in smoking intensity and COPD risk: an observational study in primary care. NPJ Prim Care Respir Med. 2017 Sep 4;27(1):50.Full text Abstract
49. Chan KH, Kurmi OP, Bennett DA, et al; China Kadoorie Biobank Collaborative Group. Solid fuel use and risks of respiratory diseases. A cohort study of 280,000 Chinese never-smokers. Am J Respir Crit Care Med. 2019 Feb 1;199(3):352-61.Full text Abstract
50. Blanc PD, Annesi-Maesano I, Balmes JR, et al. The occupational burden of nonmalignant respiratory diseases. An official American Thoracic Society and European Respiratory Society statement. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1312-34.Full text Abstract
51. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Dec;162(6):2152-8.Full text Abstract
52. Lisspers K, Larsson K, Janson C, et al. Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. NPJ Prim Care Respir Med. 2019 Dec 10;29(1):45.Full text Abstract
53. Foreman MG, Zhang L, Murphy J, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med. 2011 Aug 15;184(4):414-20.Full text Abstract
54. Ma Y, Tong H, Zhang X, et al. Chronic obstructive pulmonary disease in rheumatoid arthritis: a systematic review and meta-analysis. Respir Res. 2019 Jul 9;20(1):144.Full text Abstract
55. Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text Abstract
56. Gratziou C. Respiratory, cardiovascular and other physiological consequences of smoking cessation. Curr Med Res Opin. 2009 Feb;25(2):535-45. Abstract
57. Aubin HJ, Farley A, Lycett D, et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012 Jul 10;345:e4439.Full text Abstract
58. Rebuli ME, Rose JJ, Noël A, et al. The e-cigarette or vaping product use-associated lung injury epidemic: pathogenesis, management, and future directions: an official American Thoracic Society Workshop report. Ann Am Thorac Soc. 2023 Jan;20(1):1-17.Full text Abstract
59. Bracken-Clarke D, Kapoor D, Baird AM, et al. Vaping and lung cancer - a review of current data and recommendations. Lung Cancer. 2021 Mar;153:11-20. Abstract
60. Herbst RS, Hatsukami D, Acton D, et al. Electronic nicotine delivery systems: an updated policy statement from the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol. 2022 Dec 10;40(35):4144-55.Full text Abstract
61. United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. NBK555591. 2020 [internet publication].Full text Abstract
62. Public Health England. Improving outdoor air quality and health: review of interventions. Mar 2020 [internet publication].Full text
63. Alsallakh MA, Sivakumaran S, Kennedy S, et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales. BMC Med. 2021 May 17;19(1):124.Full text Abstract
64. Chan KPF, Ma TF, Kwok WC, et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med. 2020 Sep;171:106085.Full text Abstract
65. Huh K, Kim YE, Ji W, et al. Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a nationwide claims study. Thorax. 2021 Sep;76(9):939-41.Full text Abstract
66. Jing JY, Huang TC, Cui W, et al. Should FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction? A metaanalysis. Chest. 2009 Apr;135(4):991-8. Abstract
67. American College of Radiology. ACR appropriateness criteria: chronic dyspnea-noncardiovascular origin. 2024 [internet publication].Full text
68. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128-38.Full text Abstract
69. World Health Organization. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75(5):397-415.Full text Abstract
70. Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α(1)-antitrypsin deficiency. Eur Respir J. 2017 Nov;50(5).Full text Abstract
71. Krist AH, Davidson KW, Mangione CM, et al; US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021 Mar 9;325(10):962-70.Full text Abstract
72. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med. 2010 Aug 1;182(3):325-31.Full text Abstract
73. Johnston KN, Potter AJ, Phillips A. Measurement properties of short lower extremity functional exercise tests in people with chronic obstructive pulmonary disease: systematic review. Phys Ther. 2017 Sep 1;97(9):926-43.Full text Abstract
74. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398-420.Full text Abstract
75. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018 Feb;6(2):117-26. Abstract
76. Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020 Jan 3;21(1):3.Full text Abstract
77. Oshagbemi OA, Odiba JO, Daniel A, et al. Absolute blood eosinophil counts to guide inhaled corticosteroids therapy among patients with COPD: systematic review and meta-analysis. Curr Drug Targets. 2019;20(16):1670-9. Abstract
78. Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019 Sep;7(9):745-56. Abstract
79. Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 Dec 13;52(6):1801586.Full text Abstract
80. Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-39.Full text Abstract
81. US Preventive Services Task Force. Final recommendation statement: chronic obstructive pulmonary disease: screening. May 2022 [internet publication].Full text
82. Welte T, Vogelmeier C, Papi A. COPD: early diagnosis and treatment to slow disease progression. Int J Clin Pract. 2015 Mar;69(3):336-49.Full text Abstract
83. Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review. Am J Respir Crit Care Med. 2021 Mar 15;203(6):689-98.Full text Abstract
84. Yang IA, Ferry OR, Clarke MS, et al. Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023 Mar 27;(3):CD002991.Full text Abstract
85. Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med. 2009 May;103(5):670-91. Abstract
86. Poot CC, Meijer E, Kruis AL, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2021 Sep 8;(9):CD009437.Full text Abstract
87. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. Abstract
88. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 May 13;389(10082):1919-29. Abstract
89. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076-84. Abstract
90. Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-46.Full text Abstract
91. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 May 3;378(18):1671-80.Full text Abstract
92. Rojas-Reyes MX, García Morales OM, Dennis RJ, et al. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008532.Full text Abstract
93. Lai CC, Chen CH, Lin CYH, et al. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019 Jul 11;14:1539-48. [Erratum in: Int J Chron Obstruct Pulmon Dis. 2020 Jan 21;15:155-6.]Full text Abstract
94. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020 Jul 2;383(1):35-48. Abstract
95. Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 May 1;201(9):e56-69.Full text Abstract
96. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001387.Full text Abstract
97. Chen AM, Bollmeier SG, Finnegan PM, et al. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2008 Dec;42(12):1832-42. Abstract
98. Halpin DM, Vogelmeier C, Pieper MP, et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir Med. 2016 May;114:1-8.Full text Abstract
99. Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015 Nov 16;10(1):2495-517.Full text Abstract
100. Hilleman DE, Malesker MA, Morrow LE, et al. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009 Jun 29;4:253-63.Full text Abstract
101. Wang MT, Liou JT, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018 Feb 1;178(2):229-38.Full text Abstract
102. Wise RA, Chapman KR, Scirica BM, et al. Effect of aclidinium bromide on major cardiovascularevents and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA. 2019 May 7;321(17):1693-701.Full text Abstract
103. Gershon AS, Newman AM, Fischer HD, et al. Inhaled long-acting anticholinergics and urinary tract infection in individuals with COPD. COPD. 2017 Feb;14(1):105-12. Abstract
104. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest. 2008 Aug;134(2):255-62. Abstract
105. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011 Mar 24;364(12):1093-103.Full text Abstract
106. Decramer ML, Chapman KR, Dahl R, et al; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013 Sep;1(7):524-33. Abstract
107. Celli B, Decramer M, Kesten S, et al. UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55.Full text Abstract
108. Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008 Apr;102(4):479-87. Abstract
109. Tashkin DP, Pearle J, Iezzoni D, et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009 Feb;6(1):17-25. Abstract
110. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008 Nov;102(11):1511-20. Abstract
111. Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019 Oct 30;20(1):238.Full text Abstract
112. Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 Mar 6;(3):CD012930.Full text Abstract
113. Fukuda N, Horita N, Kaneko A, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD012066.Full text Abstract
114. Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016 Apr;10(2):89-104.Full text Abstract
115. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698-702.Full text Abstract
116. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005 Dec;60(12):992-7. Abstract
117. Lee HW, Park J, Jo J, et al. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. PLoS Med. 2019 Nov;16(11):e1002958.Full text Abstract
118. Wedzicha JA, Banerji D, Chapman KR, et al; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222-34.Full text Abstract
119. Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open. 2020 Apr 15;10(4):e037509.Full text Abstract
120. Whittaker HR, Jarvis D, Sheikh MR, et al. Inhaled corticosteroids and FEV1 decline in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2019 Dec 4;20(1):277.Full text Abstract
121. Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013 Nov;68(11):1029-36.Full text Abstract
122. Lodise TP, Li J, Gandhi HN, et al. Intraclass difference in pneumonia risk with fluticasone and budesonide in COPD: a systematic review of evidence from direct-comparison studies. Int J Chron Obstruct Pulmon Dis. 2020 Nov 11;15:2889-900.Full text Abstract
123. Yang M, Du Y, Chen H, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019 Dec;77:105950. Abstract
124. Eklöf J, Ingebrigtsen TS, Sørensen R, et al. Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease. Thorax. 2022 Jun;77(6):573-80.Full text Abstract
125. Festic E, Bansal V, Gupta E, et al. Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients; systematic review and meta-analysis. COPD. 2016 Jun;13(3):312-26.Full text Abstract
126. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet. 2009 Aug 29;374(9691):668-70. Abstract
127. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014 Mar 10;(3):CD010115.Full text Abstract
128. Dong YH, Chang CH, Lin Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014 Jun;145(6):1286-97. Abstract
129. Castellana G, Castellana M, Castellana C, et al. Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung diseases: a systematic review and meta-analysis of non-randomized studies. Int J Chron Obstruct Pulmon Dis. 2019 Sep 26;14:2219-27.Full text Abstract
130. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018 Dec 13;52(6):1801219.Full text Abstract
131. Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020 Jun 4;55(6):2000351.Full text Abstract
132. Tricco AC, Strifler L, Veroniki AA, et al. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis. BMJ Open. 2015 Oct 26;5(10):e009183. [Erratum in: BMJ Open. 2019 May 1;9(4):e009183corr1.]Full text Abstract
133. Kerkhof M, Voorham J, Dorinsky P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020 Sep;75(9):744-53.Full text Abstract
134. Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-16.Full text Abstract
135. Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021 Mar 1;203(5):553-64.Full text Abstract
136. Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. 2018 Dec 13;52(6):1801230.Full text Abstract
137. Axson EL, Lewis A, Potts J, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open. 2020 Sep 29;10(9):e036455.Full text Abstract
138. Rogliani P, Ritondo BL, Gabriele M, et al. Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings. Expert Rev Clin Pharmacol. 2020 Sep;13(9):977-90.Full text Abstract
139. Janjua S, Fortescue R, Poole P. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020 May 1;(5):CD002309.Full text Abstract
140. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med. 2023 Aug 15;208(4):406-16.Full text Abstract
141. Yappalparvi A, Balaraman AK, Padmapriya G, et al. Safety and efficacy of ensifentrine in COPD: a systemic review and meta-analysis. Respir Med. 2025 Jan;236:107863.Full text Abstract
142. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013 May;107(5):637-48. Abstract
143. Lee JS, Park DA, Hong Y, et al. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis. Int J Tuberc Lung Dis. 2013 Feb;17(2):153-62. Abstract
144. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 May;2(5):361-8. Abstract
145. Janjua S, Mathioudakis AG, Fortescue R, et al. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Jan 15;(1):CD013198.Full text Abstract
146. Herath SC, Normansell R, Maisey S, et al. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Oct 30;(10):CD009764.Full text Abstract
147. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1503-8.Full text Abstract
148. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011 Aug 25;365(8):689-98.Full text Abstract
149. Smith D, Du Rand I, Addy CL, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax. 2020 May;75(5):370-404.Full text Abstract
150. Threapleton CJ, Janjua S, Fortescue R, et al. Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 May 24;(5):CD013024.Full text Abstract
151. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023 Jul 20;389(3):205-14.Full text Abstract
152. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024 Jun 27;390(24):2274-83. Abstract
153. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017 Oct 26;377(17):1613-29.Full text Abstract
154. Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025 May 1;392(17):1710-20. Abstract
155. Ram FSF, Jones P, Jardim J, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003902.Full text Abstract
156. Jenkins CR, Wen FQ, Martin A, et al; TASCS study investigators. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. Eur Respir J. 2021 Jun 10;57(6):2003338.Full text Abstract
157. Lenferink A, Brusse-Keizer M, van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Aug 4;(8):CD011682.Full text Abstract
158. Aboumatar H, Naqibuddin M, Chung S, et al. Effect of a hospital-initiated program combining transitional care and long-term self-management support on outcomes of patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. JAMA. 2019 Oct 8;322(14):1371-80.Full text Abstract
159. Sampaio MS, Vieira WA, Bernardino ÍM, et al. Chronic obstructive pulmonary disease as a risk factor for suicide: a systematic review and meta-analysis. Respir Med. 2019 May;151:11-18.Full text Abstract
160. Russell S, Ogunbayo OJ, Newham JJ, et al. Qualitative systematic review of barriers and facilitators to self-management of chronic obstructive pulmonary disease: views of patients and healthcare professionals. NPJ Prim Care Respir Med. 2018 Jan 17;28(1):2.Full text Abstract
161. Pollok J, van Agteren JE, Esterman AJ, et al. Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 Mar 6;(3):CD012347.Full text Abstract
162. Ma RC, Yin YY, Wang YQ, et al. Effectiveness of cognitive behavioural therapy for chronic obstructive pulmonary disease patients: a systematic review and meta-analysis. Complement Ther Clin Pract. 2020 Feb;38:101071. Abstract
163. Williams MT, Johnston KN, Paquet C. Cognitive behavioral therapy for people with chronic obstructive pulmonary disease: rapid review. Int J Chron Obstruct Pulmon Dis. 2020 Apr 23;15:903-19.Full text Abstract
164. Jolly K, Sidhu MS, Hewitt CA, et al. Self management of patients with mild COPD in primary care: randomised controlled trial. BMJ. 2018 Jun 13;361:k2241.Full text Abstract
165. Long H, Howells K, Peters S, et al. Does health coaching improve health-related quality of life and reduce hospital admissions in people with chronic obstructive pulmonary disease? A systematic review and meta-analysis. Br J Health Psychol. 2019 Sep;24(3):515-46.Full text Abstract
166. Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation technique errors with metered-dose inhalers among patients with obstructive lung diseases: a systematic review and meta-analysis of US Studies. Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):267-80.Full text Abstract
167. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011 Jun;105(6):930-8.Full text Abstract
168. Rootmensen GN, van Keimpema AR, Jansen HM, et al. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv. 2010 Oct;23(5):323-8. Abstract
169. Price D, Keininger DL, Viswanad B, et al. Factors associated with appropriate inhaler use in patients with COPD - lessons from the REAL survey. Int J Chron Obstruct Pulmon Dis. 2018 Feb 26;13:695-702. [Erratum in: Int J Chron Obstruct Pulmon Dis. 2018 Jul 25;13:2253-4.]Full text Abstract
170. Maricoto T, Monteiro L, Gama JMR, et al. Inhaler technique education and exacerbation risk in older adults with asthma or chronic obstructive pulmonary disease: a meta-analysis. J Am Geriatr Soc. 2019 Jan;67(1):57-66. Abstract
171. Jia X, Zhou S, Luo D, et al. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: a systematic review and meta-analysis. J Clin Pharm Ther. 2020 Oct;45(5):904-17.Full text Abstract
172. Willard-Grace R, Chirinos C, Wolf J, et al. Lay health coaching to increase appropriate inhaler use in COPD: a randomized controlled trial. Ann Fam Med. 2020 Jan;18(1):5-14.Full text Abstract
173. Navaie M, Dembek C, Cho-Reyes S, et al. Inhaler device feature preferences among patients with obstructive lung diseases: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Jun 19;99(25):e20718.Full text Abstract
174. Tervonen T, Hawken N, Hanania NA, et al. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment. Thorax. 2020 Sep;75(9):735-43.Full text Abstract
175. Lahham A, McDonald CF, Holland AE. Exercise training alone or with the addition of activity counseling improves physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2016 Dec 8;11:3121-36.Full text Abstract
176. Vooijs M, Siemonsma PC, Heus I, et al. Therapeutic validity and effectiveness of supervised physical exercise training on exercise capacity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Clin Rehabil. 2016 Nov;30(11):1037-48. Abstract
177. Ward TJC, Plumptre CD, Dolmage TE, et al. Change in VO2peak in response to aerobic exercise training and the relationship with exercise prescription in people with COPD: a systematic review and meta-analysis. Chest. 2020 Jul;158(1):131-44. Abstract
178. Paneroni M, Vitacca M, Venturelli M, et al. The impact of exercise training on fatigue in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Pulmonology. 2020 Sep - Oct;26(5):304-13. Abstract
179. Taylor D, Jenkins AR, Parrott K, et al. Efficacy of unsupervised exercise in adults with obstructive lung disease: a systematic review and meta-analysis. Thorax. 2021 Jun;76(6):591-600. Abstract
180. Burge AT, Cox NS, Abramson MJ, et al. Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2020 Apr 16;(4):CD012626.Full text Abstract
181. Cramer H, Haller H, Klose P, et al. The risks and benefits of yoga for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Clin Rehabil. 2019 Dec;33(12):1847-62. Abstract
182. Tong H, Liu Y, Zhu Y, et al. The therapeutic effects of qigong in patients with chronic obstructive pulmonary disease in the stable stage: a meta-analysis. BMC Complement Altern Med. 2019 Sep 4;19(1):239.Full text Abstract
183. Lu Y, Li P, Li N, et al. Effects of home-based breathing exercises in subjects with COPD. Respir Care. 2020 Mar;65(3):377-87.Full text Abstract
184. Liu X, Fu C, Hu W, et al. The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ann Palliat Med. 2021 Apr;10(4):3763-82.Full text Abstract
185. Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respirology. 2013 May;18(4):616-29.Full text Abstract
186. Ferreira IM, Brooks D, White J, et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012 Dec 12;(12):CD000998.Full text Abstract
187. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):47-55.Full text Abstract
188. Hoogendoorn M, Feenstra TL, Hoogenveen RT, et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax. 2010 Aug;65(8):711-8. Abstract
189. Warnier MJ, van Riet EE, Rutten FH, et al. Smoking cessation strategies in patients with COPD. Eur Respir J. 2013 Mar;41(3):727-34. Abstract
190. van Eerd EA, van der Meer RM, van Schayck OC, et al. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Aug 20;(8):CD010744.Full text Abstract
191. Bowler RP, Hansel NN, Jacobson S, et al; for COPDGene and SPIROMICS Investigators. Electronic cigarette use in US adults at risk for or with COPD: analysis from two observational cohorts. J Gen Intern Med. 2017 Dec;32(12):1315-22.Full text Abstract
192. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019 May 20;(5):CD001287.Full text Abstract
193. Rogliani P, Matera MG, Page C, et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. 2019 May 27;20(1):104.Full text Abstract
194. Wei J, Pang CS, Han J, et al. Effect of orally administered N-acetylcysteine on chronic bronchitis: a meta-analysis. Adv Ther. 2019 Dec;36(12):3356-67. Abstract
195. Rochester CL, Alison JA, Carlin B, et al. Pulmonary rehabilitation for adults with chronic respiratory disease: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2023 Aug 15;208(4):e7-26.Full text Abstract
196. Man W, Chaplin E, Daynes E, et al. British Thoracic Society Clinical Statement on pulmonary rehabilitation. Thorax. 2023 Oct;78(suppl 5):s2-15.Full text Abstract
197. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793.Full text Abstract
198. Marciniuk DD, Brooks D, Butcher S, et al. Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease - practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010 Jul-Aug;17(4):159-68. Abstract
199. Puhan MA, Gimeno-Santos E, Cates CJ, et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 8;(12):CD005305.Full text Abstract
200. Lindenauer PK, Stefan MS, Pekow PS, et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries. JAMA. 2020 May 12;323(18):1813-23.Full text Abstract
201. Stefan MS, Pekow PS, Priya A, et al. Association between initiation of pulmonary rehabilitation and rehospitalizations in patients hospitalized with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021 Nov 1;204(9):1015-23.Full text Abstract
202. Greening NJ, Williams JE, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014 Jul 8;349:g4315.Full text Abstract
203. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med. 2009 Mar 26;360(13):1329-35. Abstract
204. Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest. 2000 Apr;117(4):976-83. Abstract
205. Malaguti C, Dal Corso S, Janjua S, et al. Supervised maintenance programmes following pulmonary rehabilitation compared to usual care for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2021 Aug 17;(8):CD013569.Full text Abstract
206. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008 Dec 16;149(12):869-78. Abstract
207. Neves LF, Reis MH, Gonçalves TR. Home or community-based pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Cad Saude Publica. 2016 Jun 20;32(6):S0102-311X2016000602001.Full text Abstract
208. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial. Thorax. 2017 Jan;72(1):57-65.Full text Abstract
209. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev. 2021 Jan 29;(1):CD013040.Full text Abstract
210. Jacobs SS, Krishnan JA, Lederer DJ, et al. Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020 Nov 15;202(10):e121-41. [Erratum in: Am J Respir Crit Care Med. 2021 Apr 15;203(8):1045-6.]Full text Abstract
211. Ekström M, Ahmadi Z, Bornefalk-Hermansson A, et al. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. Cochrane Database Syst Rev. 2016 Nov 25;(11):CD006429.Full text Abstract
212. British Thoracic Society. Air travel. Mar 2022 [internet publication].Full text
213. Edvardsen A, Akerø A, Christensen CC, et al. Air travel and chronic obstructive pulmonary disease: a new algorithm for pre-flight evaluation. Thorax. 2012 Nov;67(11):964-9.Full text Abstract
214. Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2020 Feb 4;323(5):455-65.Full text Abstract
215. Raveling T, Vonk J, Struik FM, et al. Chronic non-invasive ventilation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2021 Aug 9;(8):CD002878.Full text Abstract
216. He X, Luo L, Ma Y, et al. Efficacy of domiciliary noninvasive ventilation on clinical outcomes in posthospital chronic obstructive pulmonary disease patients: a meta-analysis of randomized controlled trials. Ann Palliat Med. 2021 May;10(5):5137-45. Abstract
217. Macrea M, Oczkowski S, Rochwerg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice fuideline. Am J Respir Crit Care Med. 2020 Aug 15;202(4):e74-87.Full text Abstract
218. Ergan B, Oczkowski S, Rochwerg B, et al. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019 Sep 28;54(3):1901003.Full text Abstract
219. Kaminska M, Rimmer KP, McKim DA, et al. Long-term non-invasive ventilation in patients with chronic obstructive pulmonary disease (COPD): 2021 Canadian Thoracic Society clinical practice guideline update. Can J Respir Crit Care Sleep Med. 2021 May 7;5(3):160-83.Full text
220. van Agteren JE, Hnin K, Grosser D, et al. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Feb 23;(2):CD012158.Full text Abstract
221. van Agteren JE, Carson KV, Tiong LU, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev. 2016 Oct 14;(10):CD001001.Full text Abstract
222. Bascarevic S, Ercegovac M, Popovic M, et al. Functional outcomes after bullectomy in group III bullous emphysema: a single-center 24-month follow-up study. J Thorac Dis. 2026 Aug 31;18(8):916.Full text Abstract
223. van Geffen WH, Slebos DJ, Herth FJ, et al. Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. Lancet Respir Med. 2019 Apr;7(4):313-24. Abstract
224. Klooster K, Slebos DJ, Zoumot Z, et al. Endobronchial valves for emphysema: an individual patient-level reanalysis of randomised controlled trials. BMJ Open Respir Res. 2017 Nov 2;4(1):e000214.Full text Abstract
225. Labarca G, Uribe JP, Pacheco C, et al. Bronchoscopic lung volume reduction with endobronchial zephyr valves for severe emphysema: a systematic review and meta-analysis. Respiration. 2019 May 22;98(3):268-78. Abstract
226. Abia-Trujillo D, Johnson MM, Patel NM, et al. Bronchoscopic lung volume reduction: a new hope for patients with severe emphysema and air trapping. Mayo Clin Proc. 2021 Feb;96(2):464-72. Abstract
227. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021 Nov;40(11):1349-79.Full text Abstract
228. Janssen DJA, Bajwah S, Boon MH, et al. European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease. Eur Respir J. 2023 Aug;62(2):2202014.Full text Abstract
229. Ekström MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014 Jan 30;348:g445.Full text Abstract
230. Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, et al. Effect of sustained-release morphine for refractory breathlessness in chronic obstructive pulmonary disease on health status: a randomized clinical trial. JAMA Intern Med. 2020 Oct 1;180(10):1306-14.Full text Abstract
231. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016 Oct 20;(10):CD007354.Full text Abstract
232. von Trott P, Oei SL, Ramsenthaler C. Acupuncture for breathlessness in advanced diseases: a systematic review and meta-analysis. J Pain Symptom Manage. 2020 Feb;59(2):327-38.e3. Abstract
233. Centers for Disease Control and Prevention. Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2025. Jul 2025 [internet publication].Full text
234. Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan 24;(1):CD001390.Full text Abstract
235. Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018 Jun 26;(6):CD002733.Full text Abstract
236. Radovanovic D, Mantero M, Sferrazza Papa GF, et al. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2016 Oct;10(10):1045-55. Abstract
237. Herth FJ, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med. 2016 Mar;4(3):185-93. Abstract
238. Zoumot Z, Kemp SV, Singh S, et al. Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial. PLoS One. 2015 Apr 8;10(4):e0122656.Full text Abstract
239. Ntenti C, Misirlis TN, Goulas A. Pharmacogenetic factors shaping treatment outcomes in chronic obstructive pulmonary disease. Genes (Basel). 2025 Mar 6;16(3):314.Full text Abstract
240. Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al. Club cell protein 16 (CC16) augmentation: a potential disease-modifying approach for chronic obstructive pulmonary disease (COPD). Expert Opin Ther Targets. 2016 Jul;20(7):869-83.Full text Abstract
241. Milne S, Li X, Hernandez Cordero AI, et al. Protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study. Thorax. 2020 Nov;75(11):934-43. Abstract
242. Bourbeau J, Bhutani M, Hernandez P, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Can J Resp Crit Care Sleep Med. 2023 Sep 8;7(4):173-91.Full text
243. US Department of Veterans Affairs. VA/DoD clinical practice guideline for the management of chronic obstructive pulmonary disease. Apr 2021 [internet publication].Full text
244. Hanson C, Bowser EK, Frankenfield DC, et al. Chronic obstructive pulmonary disease: a 2019 evidence analysis center evidence-based practice guideline. J Acad Nutr Diet. 2021 Jan;121(1):139-65.e15.Full text Abstract
245. Cardiac + Respiratory Foundation NZ. New Zealand COPD guidelines: 2025 update. Sep 2025 [internet publication].Full text
246. Lung Foundation Australia. COPD guidelines: the COPD-X plan. Dec 2025 [internet publication].Full text
247. Zider AD, Wang X, Buhr RG, et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017 Sep;152(3):494-501. Abstract
248. Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a dose-response meta-analysis. Medicine (Baltimore). 2016 Jul;95(28):e4225.Full text Abstract
249. Sun Y, Milne S, Jaw JE, et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res. 2019 Oct 29;20(1):236.Full text Abstract
250. Celli BR, Cote CG, Marin JM, et al. The Body-mass index, airflow Obstruction, Dyspnea, and Exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.Full text Abstract
251. Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J. 2014 Feb;43(2):397-408. Abstract
252. Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017 Jan 31;26(143):160070.Full text Abstract
253. Stolz D, Meyer A, Rakic J, et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur Respir J. 2014 Dec;44(6):1557-70. Abstract
254. Almagro P, Soriano JB, Cabrera FJ, et al; Working Group on COPD, Spanish Society of Internal Medicine. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014 May;145(5):972-80. Abstract
255. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005 Aug;26(2):234-41.Full text Abstract
256. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 9;169(3):219-29.Full text Abstract
257. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Nov 26;300(20):2407-16.Full text Abstract
258. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med. 2001 Apr 3;134(7):600-20. Abstract
259. Klinger JR, Hill NS. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest. 1991 Mar;99(3):715-23. Abstract
260. John M, Lange A, Hoernig S, et al. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol. 2006 Aug 28;111(3):365-70. Abstract
261. Chambellan A, Chailleux E, Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long term oxygen therapy. Chest. 2005 Sep;128(3):1201-8. Abstract
262. Xu Y, Hu T, Ding H, et al. Effects of anemia on the survival of patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Dec;14(12):1267-77. Abstract
263. Park HY, Kang D, Shin SH, et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study. Thorax. 2020 Jun;75(6):506-9.Full text Abstract
264. Janjua S, Carter D, Threapleton CJ, et al. Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2021 Jul 20;(7):CD013196.Full text Abstract
265. Iepsen UW, Jørgensen KJ, Ringbæk T, et al. A combination of resistance and endurance training increases leg muscle strength in COPD: an evidence-based recommendation based on systematic review with meta-analyses. Chron Respir Dis. 2015 May;12(2):132-45.Full text Abstract
266. UK Health Security Agency. Guidance on complete routine immunisation schedule. Jan 2025 [internet publication].Full text
267. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials. Thorax. 2019 Apr;74(4):337-45.Full text Abstract
Use of this content is subject to our disclaimer